ATE480542T1 - Pyrroloä1,2-düä1,2-4ütriazin als inhibitoren von c-jun-n-terminal-kinasen (jnk) und p-38-kinasen - Google Patents

Pyrroloä1,2-düä1,2-4ütriazin als inhibitoren von c-jun-n-terminal-kinasen (jnk) und p-38-kinasen

Info

Publication number
ATE480542T1
ATE480542T1 AT05814296T AT05814296T ATE480542T1 AT E480542 T1 ATE480542 T1 AT E480542T1 AT 05814296 T AT05814296 T AT 05814296T AT 05814296 T AT05814296 T AT 05814296T AT E480542 T1 ATE480542 T1 AT E480542T1
Authority
AT
Austria
Prior art keywords
kinases
jnk
jun
pyrroloä1
düä1
Prior art date
Application number
AT05814296T
Other languages
English (en)
Inventor
Qing Dong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE480542T1 publication Critical patent/ATE480542T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05814296T 2004-10-26 2005-10-25 Pyrroloä1,2-düä1,2-4ütriazin als inhibitoren von c-jun-n-terminal-kinasen (jnk) und p-38-kinasen ATE480542T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62251904P 2004-10-26 2004-10-26
PCT/US2005/038071 WO2006047354A1 (en) 2004-10-26 2005-10-25 Pyrrolo [1,2-d][1,2-4]triazine as inhibitors of c-jun n terminal kinases (jnk) and p-38 kinases

Publications (1)

Publication Number Publication Date
ATE480542T1 true ATE480542T1 (de) 2010-09-15

Family

ID=35825463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05814296T ATE480542T1 (de) 2004-10-26 2005-10-25 Pyrroloä1,2-düä1,2-4ütriazin als inhibitoren von c-jun-n-terminal-kinasen (jnk) und p-38-kinasen

Country Status (16)

Country Link
US (1) US7855288B2 (de)
EP (1) EP1807431B1 (de)
JP (1) JP2008517933A (de)
KR (1) KR20070064350A (de)
CN (1) CN101035791B (de)
AT (1) ATE480542T1 (de)
AU (1) AU2005299730B2 (de)
BR (1) BRPI0518277A2 (de)
CA (1) CA2580475A1 (de)
DE (1) DE602005023504D1 (de)
ES (1) ES2350771T3 (de)
MX (1) MX2007004935A (de)
PL (1) PL1807431T3 (de)
PT (1) PT1807431E (de)
RU (1) RU2007119448A (de)
WO (1) WO2006047354A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007141224A2 (en) * 2006-06-02 2007-12-13 Laboratoires Serono Sa Jnk inhibitors for treatment of skin diseases
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
US20100183633A1 (en) * 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
US8349832B2 (en) 2009-09-02 2013-01-08 Canthera Therapeutics Compounds and compositions for treating cancer
US8318737B2 (en) 2009-09-02 2012-11-27 Canthera Therapeutics Inc. Compounds and compositions for treating cancer
US9102602B2 (en) 2010-11-29 2015-08-11 Nissan Chemical Industries, Ltd. Method for producing isothiocyanate compound
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
WO2014143606A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750522A (en) * 1995-07-13 1998-05-12 American Home Products Corporation Pyrrolo 1,2-d! 1,2,4!triazine derivatives
GEP20063915B (en) * 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
PT1497019E (pt) * 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase

Also Published As

Publication number Publication date
PL1807431T3 (pl) 2011-03-31
KR20070064350A (ko) 2007-06-20
US20080253988A1 (en) 2008-10-16
EP1807431B1 (de) 2010-09-08
PT1807431E (pt) 2010-11-18
DE602005023504D1 (de) 2010-10-21
US7855288B2 (en) 2010-12-21
AU2005299730B2 (en) 2009-11-12
JP2008517933A (ja) 2008-05-29
RU2007119448A (ru) 2008-12-10
BRPI0518277A2 (pt) 2008-11-11
AU2005299730A1 (en) 2006-05-04
MX2007004935A (es) 2007-06-12
CN101035791B (zh) 2010-12-08
CN101035791A (zh) 2007-09-12
EP1807431A1 (de) 2007-07-18
ES2350771T3 (es) 2011-01-26
CA2580475A1 (en) 2006-05-04
WO2006047354A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
NO20071127L (no) Triazoloftalaziner
MX2007005408A (es) Compuestos de aminoquinazolinas.
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ATE552834T1 (de) Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
DE602005023333D1 (de) Kinaseinhibitoren
DE60334536D1 (de) Furylverbindungen
CY1107846T1 (el) Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες
NO20044995L (no) Heterosykliske forbindelser
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
MX2007005932A (es) 1-alquinil-2-ariloxialquilamidas y su uso como fungicidas.
ATE400567T1 (de) Kinaseinhibitoren
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
NO20081292L (no) Pentasykliske kinaseinhibitorer
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
EA201000566A1 (ru) Гетероциклические сетр ингибиторы
ATE480542T1 (de) Pyrroloä1,2-düä1,2-4ütriazin als inhibitoren von c-jun-n-terminal-kinasen (jnk) und p-38-kinasen
EA200600607A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
SE0400208D0 (sv) Chemical compounds
MY148644A (en) New pharmaceutical compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1807431

Country of ref document: EP